Cargando…
Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation
Intermittently administered parathyroid hormone (PTH 1-34) has been shown to promote bone formation in both human and animal studies. The hormone and its analogues stimulate both bone formation and resorption, and as such at low doses are now in clinical use for the treatment of severe osteoporosis....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5227055/ https://www.ncbi.nlm.nih.gov/pubmed/28062525 http://dx.doi.org/10.1302/2046-3758.61.BJR-2016-0085.R1 |
_version_ | 1782493751621451776 |
---|---|
author | Osagie-Clouard, L. Sanghani, A. Coathup, M. Briggs, T. Bostrom, M. Blunn, G. |
author_facet | Osagie-Clouard, L. Sanghani, A. Coathup, M. Briggs, T. Bostrom, M. Blunn, G. |
author_sort | Osagie-Clouard, L. |
collection | PubMed |
description | Intermittently administered parathyroid hormone (PTH 1-34) has been shown to promote bone formation in both human and animal studies. The hormone and its analogues stimulate both bone formation and resorption, and as such at low doses are now in clinical use for the treatment of severe osteoporosis. By varying the duration of exposure, parathyroid hormone can modulate genes leading to increased bone formation within a so-called ‘anabolic window’. The osteogenic mechanisms involved are multiple, affecting the stimulation of osteoprogenitor cells, osteoblasts, osteocytes and the stem cell niche, and ultimately leading to increased osteoblast activation, reduced osteoblast apoptosis, upregulation of Wnt/β-catenin signalling, increased stem cell mobilisation, and mediation of the RANKL/OPG pathway. Ongoing investigation into their effect on bone formation through ‘coupled’ and ‘uncoupled’ mechanisms further underlines the impact of intermittent PTH on both cortical and cancellous bone. Given the principally catabolic actions of continuous PTH, this article reviews the skeletal actions of intermittent PTH 1-34 and the mechanisms underlying its effect. Cite this article: L. Osagie-Clouard, A. Sanghani, M. Coathup, T. Briggs, M. Bostrom, G. Blunn. Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation. Bone Joint Res 2017;6:14–21. DOI: 10.1302/2046-3758.61.BJR-2016-0085.R1. |
format | Online Article Text |
id | pubmed-5227055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-52270552017-02-01 Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation Osagie-Clouard, L. Sanghani, A. Coathup, M. Briggs, T. Bostrom, M. Blunn, G. Bone Joint Res Instructional Review - Research Intermittently administered parathyroid hormone (PTH 1-34) has been shown to promote bone formation in both human and animal studies. The hormone and its analogues stimulate both bone formation and resorption, and as such at low doses are now in clinical use for the treatment of severe osteoporosis. By varying the duration of exposure, parathyroid hormone can modulate genes leading to increased bone formation within a so-called ‘anabolic window’. The osteogenic mechanisms involved are multiple, affecting the stimulation of osteoprogenitor cells, osteoblasts, osteocytes and the stem cell niche, and ultimately leading to increased osteoblast activation, reduced osteoblast apoptosis, upregulation of Wnt/β-catenin signalling, increased stem cell mobilisation, and mediation of the RANKL/OPG pathway. Ongoing investigation into their effect on bone formation through ‘coupled’ and ‘uncoupled’ mechanisms further underlines the impact of intermittent PTH on both cortical and cancellous bone. Given the principally catabolic actions of continuous PTH, this article reviews the skeletal actions of intermittent PTH 1-34 and the mechanisms underlying its effect. Cite this article: L. Osagie-Clouard, A. Sanghani, M. Coathup, T. Briggs, M. Bostrom, G. Blunn. Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation. Bone Joint Res 2017;6:14–21. DOI: 10.1302/2046-3758.61.BJR-2016-0085.R1. 2017-01-12 /pmc/articles/PMC5227055/ /pubmed/28062525 http://dx.doi.org/10.1302/2046-3758.61.BJR-2016-0085.R1 Text en © 2017 Osagie-Clouard et al. This is an open-access article distributed under the terms of the Creative Commons Attributions licence (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited. |
spellingShingle | Instructional Review - Research Osagie-Clouard, L. Sanghani, A. Coathup, M. Briggs, T. Bostrom, M. Blunn, G. Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation |
title | Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation |
title_full | Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation |
title_fullStr | Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation |
title_full_unstemmed | Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation |
title_short | Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation |
title_sort | parathyroid hormone 1-34 and skeletal anabolic action: the use of parathyroid hormone in bone formation |
topic | Instructional Review - Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5227055/ https://www.ncbi.nlm.nih.gov/pubmed/28062525 http://dx.doi.org/10.1302/2046-3758.61.BJR-2016-0085.R1 |
work_keys_str_mv | AT osagieclouardl parathyroidhormone134andskeletalanabolicactiontheuseofparathyroidhormoneinboneformation AT sanghania parathyroidhormone134andskeletalanabolicactiontheuseofparathyroidhormoneinboneformation AT coathupm parathyroidhormone134andskeletalanabolicactiontheuseofparathyroidhormoneinboneformation AT briggst parathyroidhormone134andskeletalanabolicactiontheuseofparathyroidhormoneinboneformation AT bostromm parathyroidhormone134andskeletalanabolicactiontheuseofparathyroidhormoneinboneformation AT blunng parathyroidhormone134andskeletalanabolicactiontheuseofparathyroidhormoneinboneformation |